IFF Pharma Solutions: Paving the Way for Superior Suspensions

Shawn Branning, Global Strategic Marketing Manager at IFF – Pharma Solutions
Oral suspensions are a trending delivery format, due to their highly customizable nature, increased bioavailability, and ability to provide appropriate dosing for all patients. In addition, they’re easy to swallow and offer an appealing sensory experience – leading to enhanced patient compliance.
However, suspensions require a careful balance of ingredients to ensure a positive sensory experience, along with drug efficacy. In addition to the active pharmaceutical ingredient (API), there are multiple excipients needed to ensure a uniform and stable drug product, with pleasant taste and mouthfeel. By adding the right blend of polymers, formulators can ensure that their suspension is stable and effective, while also appealing to patients.
Common Formulation Challenges
Like any drug, there are several challenges formulators face when creating suspensions, including:
- Ensuring a uniform, stable drug product. Even the most time-tested pharmaceutical ingredients can falter if they’re not paired with the right thickening and suspending agents, which results in destabilized formulations that don’t perform as intended.
- Maintaining viscosity and pourability of the drug for efficacious drug delivery. At rest, more viscosity is needed to help stabilize the active pharmaceutical agent within the suspension to prevent sedimentation and aggregation of the particles.
- Retaining sensory attributes, like mouthfeel and taste, for a pleasant drug experience. A better sensory experience leads to increased patient compliance. However, the challenge lies in taste masking bitter APIs and ensuring mouthfeel isn’t chalky or gritty.
How Can IFF Pharma Solutions Help?
Our broad range of excipients offers formulators the solutions needed to face these formulation challenges head-on. Those struggling to ensure uniformity and stability can consider Avicel® colloidal microcrystalline cellulose (cMCC). It forms a gel-like network, is thixotropic and remains stable over a wide range of pH and temperatures. It also has a long shelf-life and superior mouthfeel, making it an ideal suspending aid.
Challenges related to viscosity and pourability can be mitigated with the use of GRINDSTED® Xanthan PRM. Its pronounced shear-thinning behavior enables handling of even highly viscous solutions. It can be used as a secondary ingredient to another suspending agent such as cMCC, especially as a viscosifier, while also adding to the stabilization of oral liquid formulations.
Ingredients in a suspension can oftentimes work against each other to create an end-product that’s gritty or chalky. These textural aspects can be easily adjusted by utilizing different excipients at varying levels. For example, low-use levels of GRINDSTED® Xanthan Gum or TEXTURECEL™ NaCMC can be used to improve mouthfeel; TEXTURECEL™ NaCMC also provides clear and transparent solutions with no taste or odor.
Helping Drive the Future of Pharma
By working with IFF, formulators have access to a streamlined supply of excipient solutions, as well as the added benefits of our broad portfolio, regulatory support, and expertise as a pharmaceutical-focused business – all of which ensure an optimized end-product that achieves the desired results.
We’re interested in being more than just a supplier. We’re here to build partnerships that help our customers deliver a greater variety of drug delivery formats that patients need and will be more likely to take.

Related News
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Say hello to the CPHI Exhibitor Spotlight!
We’re kicking off a brand-new series where we shine the spotlight on some of the amazing companies gearing up to shake things up at CPHI Americas 2025 this May! The first company in our spotlight is TAPI, who are set to make a splash at its ve... -
News CPHI Podcast Series: How to build a successful CDMO partnership
The latest in our series for the CPHI Podcast Series focuses on partnerships, specifically those between pharma companies and CDMOs. Expert Christine Fürst from Vetter comments on how to make successful and lasting partnerships in the industr... -
News How GLP-1 agonists are reshaping drug delivery innovations
GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int... -
News 2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains
A new year, a new Pharma Trends Outlook report! The 2025 Pharma Trends Outlook report examines key changes expected in the pharmaceutical industry for the coming year, particularly in regards to the supply chain.
-
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News Closing 2024 with Editors' picks of top articles from the past year
Coming to the end of 2024 and it’s certainly been a busy year, for CPHI and for the rest of the pharmaceutical and healthcare industry. Topics of conversation throughout the last 12 months have been varied, touching on the technical, to the polit...